Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.
Cutaneous inflammatory diseases such as psoriasis vulgaris and atopic dermatitis are associated with altered keratinocyte function, as well as with a particular cytokine production profile of skin-infiltrating T lymphocytes. In this study we show that normal human epidermal keratinocytes express a functional type II oncostatin-M (OSM) receptor (OSMR) consisting of the gp130 and OSMRbeta components, but not the type I OSMR. The type II OSMR is expressed in skin lesions from both psoriatic patients and those with atopic dermatitis. Its ligand, OSM, induces via the recruitment of the STAT3 and MAP kinase pathways a gene expression profile in primary keratinocytes and in a reconstituted epidermis that is characteristic of proinflammatory and innate immune responses. Moreover, OSM is a potent stimulator of keratinocyte migration in vitro and increases the thickness of a reconstituted epidermis. OSM transcripts are enhanced in both psoriatic and atopic dermatitic skin as compared with healthy skin and mirror the enhanced production of OSM by T cells isolated from diseased lesions. Results from a microarray analysis comparing the gene-modulating effects of OSM with those of 33 different cytokines indicate that OSM is a potent keratinocyte activator similar to TNF-alpha, IL-1, IL-17, and IL-22 and that it acts in synergy with the latter cytokines in the induction of S100A7 and beta-defensin 2 expression, characteristic of psoriatic skin. Taken together, these results demonstrate that OSM and its receptor play an important role in cutaneous inflammatory responses in general and that the specific effects of OSM are associated with distinct inflammatory diseases depending on the cytokine environment.
Boniface
Katia
K
UPRES-EA 3806, Centre Hospitalier de l'Université de Poitiers, Poitiers, France.
Diveu
Caroline
C
Morel
Franck
F
Pedretti
Nathalie
N
Froger
Josy
J
Ravon
Elisa
E
Garcia
Martine
M
Venereau
Emilie
E
Preisser
Laurence
L
Guignouard
Emmanuel
E
Guillet
Gérard
G
Dagregorio
Guy
G
Pène
Jérôme
J
Moles
Jean-Pierre
JP
Yssel
Hans
H
Chevalier
Sylvie
S
Bernard
François-Xavier
FX
Gascan
Hugues
H
Lecron
Jean-Claude
JC
D002465:Cell Movement; D002478:Cells, Cultured; D003872:Dermatitis / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D005786:Gene Expression Regulation; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D015603:Keratinocytes / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D053683:Oncostatin M / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D053679:Receptors, Oncostatin M, Type II / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D050796:STAT3 Transcription Factor / Q000378:metabolism; D012867:Skin / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology*
D053679:Receptors, Oncostatin M, Type II; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D053683:Oncostatin M; D020929:Mitogen-Activated Protein Kinase Kinases